Disclosed herein is a composition for vaginal administration of an active agent or salt to a subject, the composition comprising said active agent or salt thereof, a bioadhesive and an emulsion. Also disclosed herein are methods of treating the symptoms of disease by vaginal administration of a pharmaceutical composition to a subject, and kits containing the pharmaceutical composition. The present invention is a method comprising vaginal administration of a pharmaceutical composition to a subject, for example in the form of an emulsion containing an active agent or a salt thereof and a bioadhesive substance, wherein the pharmaceutical composition is from about 10 mg to about Administered in a dose of 400 mg of the active agent or a salt thereof； the vaginal administration of the pharmaceutical composition comprising administration of the active agent into the peritoneal cavity of the subject for at least about 8 hours after the administration of the pharmaceutical composition. Providing a substantially zero-order release rate profile of被験体への活性剤または塩の経膣投与のための組成物であって、前記活性剤またはその塩、生体接着物質およびエマルジョンを含む組成物が本明細書に開示される。被験体への医薬組成物の経膣投与により疾患の症状を処置する方法、および医薬組成物を含むキットも本明細書に開示される。本発明は、例えば、活性剤またはその塩および生体接着物質を含むエマルジョンの形態で医薬組成物を被験体に経膣投与することを含む方法であって、前記医薬組成物を、約１０ｍｇ～約４００ｍｇの前記活性剤またはその塩の用量で投与し；前記医薬組成物の前記経膣投与が、前記医薬組成物の前記投与後少なくとも約８時間にわたって、前記被験体の腹膜腔への前記活性剤の実質的にゼロ次の放出速度プロファイルをもたらす、方法を提供する。
